GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
- C5226 γ-Linolenic Acid methyl esterSummary: weak leukotriene B4 (LTB4) receptor antagonist
- C5246 2-Ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridineSummary: nonpeptidic angiotensin II receptor antagonist
- C5279 TG4-155Summary: brain penetrant EP2 antagonist
- C5385 Butenoyl PAFSummary: PAF receptor agonist
- C5389 (±)trans-2,5-bis-(3,4,5-Trimethoxyphenyl)-1,3-dioxolaneSummary: PAF receptor antagonist
- C5552 TetrahydromagnololSummary: peripheral CB2 receptor agonist
- C5311 NESS 0327Summary: extremely potent cannabinoid (CB) receptor antagonist
- C5282 Adenosine Kinase Inhibitor (hydrate)Summary: inhibitor of adenosine kinase
- C5286 (R,S)-AtenololSummary: β1-adrenergic receptor antagonist
- C5329 Calindol (hydrochloride)Summary: activator of the calcium-sensing receptor (CaSR)